A carregar...
Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines
BACKGROUND: Lapatinib, a tyrosine kinase inhibitor of HER2 and EGFR and is approved, in combination with capecitabine, for the treatment of trastuzumab-refractory metastatic breast cancer. In order to establish a possible gene expression response to lapatinib, a panel of breast cancer cell lines wit...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3439312/ https://ncbi.nlm.nih.gov/pubmed/22709873 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-11-41 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|